Literature DB >> 28208969

Acute Presentation of Juvenile Dermatomyositis with Subclinical Cardiac Involvement: A Rare Case.

Rhythm Khera1, Shrayash Khare2, Shailendra Kumar Singh1.   

Abstract

Cardiac involvements are common in patients with Dermatomyositis, most of which are not severe enough to present definite or readily observable symptoms. However, Cardiovascular (CVS) manifestations constitute a major cause of death in these patients. The most frequently reported clinically evident of CVS manifestations in-patient of dermatomyositis are Congestive Heart Failure (CHF), conduction aberrations, that may predispose to complete heart block and coronary artery disease. The principal pathophysiological mechanisms that may produce these cardiac manifestations involve coronary artery disease as well as small vessels vasculitis of the myocardium. Our case of a seven-year-old boy represent a unique manifestation of prolong PR interval with no overt clinical manifestation and who responded well to immunosuppressive treatment. His clinical, laboratory and investigative features of Juvenile Dermatomyositis (JDM) is presented here. It is hoped that this case will heighten the index of suspicion of cardiac condition in patients with JDM among medical practitioners.

Entities:  

Keywords:  Childhood myopathy; ECG manifestations; Idiopathic inflammatory muscle disease

Year:  2016        PMID: 28208969      PMCID: PMC5296542          DOI: 10.7860/JCDR/2016/20925.9008

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

1.  MR imaging of primary skeletal muscle diseases in children.

Authors:  Wing P Chan; Gin-Chung Liu
Journal:  AJR Am J Roentgenol       Date:  2002-10       Impact factor: 3.959

2.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

Authors:  Lauren M Pachman; Rebecca Lipton; Rosalind Ramsey-Goldman; Eli Shamiyeh; Kathy Abbott; Eduardo P Mendez; Alan Dyer; Deborah Mc Curdy; Larry Vogler; Ann Reed; Gail Cawkwell; Lawrence Zemel; Christy Sandborg; Rafael Rivas-Chacon; Christine Hom; Norman Ilowite; Abraham Gedalia; Jonathan Gitlin; Michael Borzy
Journal:  Arthritis Rheum       Date:  2005-04-15

3.  Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Frederick W Miller
Journal:  JAMA       Date:  2011-01-12       Impact factor: 56.272

4.  Outcome in juvenile dermatomyositis.

Authors:  Vaidehi Chowdhary; Anupam Wakhlu; Amita Agarwal; Ramnath Misra
Journal:  Indian Pediatr       Date:  2002-10       Impact factor: 1.411

Review 5.  Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review.

Authors:  Lu Zhang; Guo-chun Wang; Li Ma; Ning Zu
Journal:  Clin Cardiol       Date:  2012-07-30       Impact factor: 2.882

6.  The incidence of juvenile dermatomyositis: results from a nation-wide study.

Authors:  D P Symmons; J A Sills; S M Davis
Journal:  Br J Rheumatol       Date:  1995-08

7.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

8.  [Originators and eponyms of dermatomyositis : Ernst Leberecht Wagner (1821-1888) and Heinrich Unverricht (1853-1912)].

Authors:  W Keitel; H-P Wolff
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

9.  Twelve years experience of juvenile dermatomyositis in North India.

Authors:  Surjit Singh; Arun Bansal
Journal:  Rheumatol Int       Date:  2005-09-15       Impact factor: 3.580

10.  Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.

Authors:  Liza J McCann; Jamie J Kirkham; Lucy R Wedderburn; Clarissa Pilkington; Adam M Huber; Angelo Ravelli; Duncan Appelbe; Paula R Williamson; Michael W Beresford
Journal:  Trials       Date:  2015-06-12       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.